Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free CALA Stock Alerts

Calithera Biosciences (CALA) Competitors

Calithera Biosciences logo
$0.0003 +0.00 (+200.00%)
As of 10/14/2026 09:30 AM Eastern
Compare

CALA vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Calithera Biosciences stock or one of its competitors? Calithera Biosciences's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calithera Biosciences compare to 60 Degrees Pharmaceuticals?

Calithera Biosciences (NASDAQ:CALA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

60 Degrees Pharmaceuticals has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Calithera Biosciences. 60 Degrees Pharmaceuticals' average media sentiment score of 1.39 beat Calithera Biosciences' score of 0.67 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Calithera Biosciences Positive
60 Degrees Pharmaceuticals Positive

Summary

60 Degrees Pharmaceuticals beats Calithera Biosciences on 3 of the 3 factors compared between the two stocks.

How does Calithera Biosciences compare to Biofrontera?

Calithera Biosciences (NASDAQ:CALA) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Biofrontera had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Calithera Biosciences. Biofrontera's average media sentiment score of 0.91 beat Calithera Biosciences' score of 0.67 indicating that Biofrontera is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Calithera Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biofrontera
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biofrontera has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

Summary

Biofrontera beats Calithera Biosciences on 3 of the 3 factors compared between the two stocks.

How does Calithera Biosciences compare to Cingulate?

Calithera Biosciences (NASDAQ:CALA) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Calithera Biosciences. Cingulate's average media sentiment score of 1.41 beat Calithera Biosciences' score of 0.67 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
Calithera Biosciences Positive
Cingulate Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
CingulateN/AN/AN/AN/AN/A

Summary

Cingulate beats Calithera Biosciences on 2 of the 2 factors compared between the two stocks.

How does Calithera Biosciences compare to Clever Leaves?

Calithera Biosciences (NASDAQ:CALA) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Calithera Biosciences has a beta of -1.52, suggesting that its share price is 252% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3892.08, suggesting that its share price is 389,108% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, Calithera Biosciences had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Clever Leaves. Calithera Biosciences' average media sentiment score of 0.67 beat Clever Leaves' score of 0.00 indicating that Calithera Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Calithera Biosciences Positive
Clever Leaves Neutral

6.9% of Clever Leaves shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Clever Leaves has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A

Summary

Clever Leaves beats Calithera Biosciences on 5 of the 8 factors compared between the two stocks.

How does Calithera Biosciences compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, Calithera Biosciences had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Comera Life Sciences. Calithera Biosciences' average media sentiment score of 0.67 beat Comera Life Sciences' score of 0.00 indicating that Calithera Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Comera Life Sciences Neutral
Calithera Biosciences Positive

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Summary

Calithera Biosciences beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

Export
MetricCalithera BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.14B$7.19B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00655.20208.5319.36
Price / SalesN/A749.06557.5674.68
Price / CashN/A84.0876.6852.75
Price / BookN/A9.1510.515.92
Net Income-$39.65M$2.82B$3.50B$380.90M
7 Day PerformanceN/A-3.79%-3.49%-3.85%
1 Month PerformanceN/A-7.63%-7.76%-6.37%
1 Year PerformanceN/A-6.12%0.82%-6.01%

Calithera Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALA
Calithera Biosciences
N/A$0.00
+200.0%		N/A+50.0%$1KN/AN/A60
SXTPW
60 Degrees Pharmaceuticals
N/A$0.02
flat		N/A-45.0%$0.00$1.11MN/A3
BFRIW
Biofrontera
N/A$0.01
-21.0%		N/A-94.4%$0.00$46.18MN/A94
CINGW
Cingulate
N/A$0.01
flat		N/A-86.6%$0.00N/AN/A14
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel